Implementing the Decision-Aid for Lupus (IDEAL Strategy)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- University of Alabama at Birmingham
- Study ID
- NCT03735238
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SMILE Computerized Decision-Aid — OTHERSMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
Study Details
The study will attempt to put into practice a shared decision making (SDM) strategy, using an individualized, computerized decision- aid (DA) for Systemic lupus erythematosus (SLE).
Key Dates
- Start date
- Dec 15, 2018
- Status verified
- Sep 2025
- Primary completion
- Nov 15, 2024
- Completion
- Jun 10, 2025
Study Design
- Enrollment
- 1,895 participants (actual)
Arms
- Arm: Lupus PatientsAll adult lupus patients, regardless of if they are having an active flare
Primary Outcome Measure
Penetration/Reach: Number of Eligible Participants at Each Clinical Site Who Enrolled Divided by the Number of Eligible Participants at Each Clinical Site, Expressed as Overall Percent [ Time Frame: 24 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | - |
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusPHASE3 · Enrolling By Invitation · UCB Biopharma SRL · Birmingham, Alabama
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).PHASE3 · Recruiting · Novartis Pharmaceuticals · Anniston, Alabama
- A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)PHASE4 · Recruiting · GlaxoSmithKline · Anniston, Alabama